Ad5/3 is able to avoid neutralization by binding to erythrocytes and lymphocytes.
Adenocarcinoma of Lung
/ immunology
Adenoviridae
/ classification
Animals
Antibodies, Neutralizing
/ immunology
Apoptosis
Cell Proliferation
Erythrocytes
/ metabolism
Female
Humans
Lung Neoplasms
/ immunology
Lymphocytes
/ metabolism
Mice
Mice, SCID
Oncolytic Virotherapy
/ methods
Transduction, Genetic
Tumor Cells, Cultured
Virus Replication
Xenograft Model Antitumor Assays
Journal
Cancer gene therapy
ISSN: 1476-5500
Titre abrégé: Cancer Gene Ther
Pays: England
ID NLM: 9432230
Informations de publication
Date de publication:
05 2021
05 2021
Historique:
received:
02
07
2020
accepted:
02
09
2020
revised:
24
08
2020
pubmed:
14
9
2020
medline:
1
2
2022
entrez:
13
9
2020
Statut:
ppublish
Résumé
Oncolytic adenoviruses are promising cancer therapeutic agents. Clinical data have shown adenoviruses' ability to transduce tumors after systemic delivery in human cancer patients, despite antibodies. In the present work, we have focused on the interaction of a chimeric adenovirus Ad5/3 with human lymphocytes and human erythrocytes. Ad5/3 binding with human lymphocytes and erythrocytes was observed to occur in a reversible manner, which allowed viral transduction of tumors, and oncolytic potency of Ad5/3 in vitro and in vivo, with or without neutralizing antibodies. Immunodeficient mice bearing xenograft tumors showed enhanced tumor transduction following systemic administration, when Ad5/3 virus was bound to lymphocytes or erythrocytes (P < 0.05). In conclusion, our findings reveal that chimeric Ad5/3 adenovirus reaches non-injected tumors in the presence of neutralizing antibodies: it occurs through reversible binding to lymphocytes and erythrocytes.
Identifiants
pubmed: 32920593
doi: 10.1038/s41417-020-00226-z
pii: 10.1038/s41417-020-00226-z
pmc: PMC8119244
doi:
Substances chimiques
Antibodies, Neutralizing
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
442-454Références
J Virol. 2005 Jun;79(12):7478-91
pubmed: 15919903
Gene Ther. 2003 Jun;10(12):1012-7
pubmed: 12776158
Nat Med. 2011 Jan;17(1):96-104
pubmed: 21151137
Cytokine Growth Factor Rev. 2010 Apr-Jun;21(2-3):127-34
pubmed: 20399700
Mol Ther. 2010 Oct;18(10):1874-84
pubmed: 20664527
J Virol. 1996 Jul;70(7):4502-8
pubmed: 8676475
Curr Gene Ther. 2011 Aug;11(4):241-58
pubmed: 21453281
Cancer Gene Ther. 2002 Mar;9(3):254-9
pubmed: 11896441
Hum Gene Ther. 2008 Dec;19(12):1415-9
pubmed: 18795826
J Cell Biochem. 2009 Nov 1;108(4):778-90
pubmed: 19711370
Gene Ther. 2005 Jan;12(1):87-94
pubmed: 15385953
Adv Virol. 2012;2012:805629
pubmed: 22400027
J Immunother Cancer. 2017 Sep 19;5(1):71
pubmed: 28923104
Sci Transl Med. 2012 Jun 13;4(138):138ra77
pubmed: 22700953
Sci Rep. 2019 Dec 24;9(1):19742
pubmed: 31875042
J Virol. 2011 Jul;85(13):6390-402
pubmed: 21525338
Mol Ther. 2006 Jul;14(1):118-28
pubmed: 16580883
Cell. 1993 Apr 23;73(2):309-19
pubmed: 8477447
Mol Ther. 2012 Sep;20(9):1821-30
pubmed: 22871667
Mol Ther. 2009 Oct;17(10):1667-76
pubmed: 19690519
Mol Ther Oncolytics. 2016 Dec 31;4:77-86
pubmed: 28345026
Cancer Res. 2002 Feb 15;62(4):1063-8
pubmed: 11861383
Oncotarget. 2015 Feb 28;6(6):4467-81
pubmed: 25714011
Mol Ther. 2015 Oct;23(10):1641-52
pubmed: 26156245
Clin Microbiol Rev. 2009 Oct;22(4):552-63
pubmed: 19822888
Nature. 2011 Aug 31;477(7362):99-102
pubmed: 21886163
Blood. 2009 Feb 26;113(9):1909-18
pubmed: 19131551
J Clin Oncol. 2004 May 1;22(9):1546-52
pubmed: 15051757
Mol Ther. 2016 Feb;24(1):6-16
pubmed: 26478249
Ann Med. 2005;37(1):33-43
pubmed: 15902845
J Virol. 1968 Oct;2(10):1064-75
pubmed: 5723709
Mol Ther. 2002 Jun;5(6):695-704
pubmed: 12027553
Proc Natl Acad Sci U S A. 2007 Mar 20;104(12):4937-42
pubmed: 17360346
Gene Ther. 2008 Jun;15(12):921-9
pubmed: 18401431
J Virol. 1993 Sep;67(9):5198-205
pubmed: 8350395
J Clin Oncol. 2003 Jul 1;21(13):2508-18
pubmed: 12839017
Compr Physiol. 2013 Apr;3(2):567-98
pubmed: 23720323
J Virol. 1995 Apr;69(4):2257-63
pubmed: 7533853
Gene Ther. 2001 May;8(10):746-59
pubmed: 11420638
Mol Ther Oncolytics. 2018 Nov 06;11:109-121
pubmed: 30569015
J Virol. 1988 Jul;62(7):2321-8
pubmed: 3373570
Cancer Gene Ther. 2016 Dec;23(12):411-414
pubmed: 27767087
Int J Cancer. 2004 Jul 1;110(4):475-80
pubmed: 15122578
Gene. 2002 Feb 20;285(1-2):69-77
pubmed: 12039033
Cancer Gene Ther. 1999 Nov-Dec;6(6):499-504
pubmed: 10608346
Clin Cancer Res. 2002 Jan;8(1):275-80
pubmed: 11801569
Oncoimmunology. 2012 Sep 1;1(6):979-981
pubmed: 23162778
Br J Cancer. 2005 Apr 25;92(8):1414-20
pubmed: 15812558
Clin Cancer Res. 2003 Feb;9(2):693-702
pubmed: 12576437
Mol Ther. 2006 Jul;14(1):107-17
pubmed: 16690359
Anticancer Res. 2007 Jul-Aug;27(4B):2311-6
pubmed: 17695519
Future Oncol. 2006 Feb;2(1):137-43
pubmed: 16556080
Clin Cancer Res. 2006 May 15;12(10):3137-44
pubmed: 16707613
Oncoimmunology. 2016 Dec 7;6(2):e1265717
pubmed: 28344872
Mol Cancer Ther. 2007 Feb;6(2):742-51
pubmed: 17308070
Cancer Res. 2002 Nov 1;62(21):6070-9
pubmed: 12414631
Cancer Gene Ther. 2011 Apr;18(4):288-96
pubmed: 21183947
Gene Ther. 2006 Aug;13(15):1166-77
pubmed: 16625245